Drug dosage determination devices and methods
Patent Information
- Application Number
- HK62022057202
- Authority / Receiving Office
- HK · HK
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-10-11
- Filing Date
- 2022-07-22
- Publication Date
- 2026-08-28
AI Technical Summary
Existing technologies struggle to effectively and accurately determine a patient's medication administration regimen, especially for medications that require long-term, regular administration, particularly those in multiple dosage forms. This leads to complexity, potential inconvenience, and cost for healthcare professionals when selecting appropriate administration regimens.
By using computing devices and methods, patient-related parameters are received, all minimum combinations of different dosage forms are calculated, a subset of combinations that meet multiple criteria is selected, and the optimal administration plan is output. Taking into account the complexity of drug dosage, concentration, administration interval and multiple time periods, the combination of drug dosage forms is optimized to reduce inconvenience and cost.
It enables efficient and accurate selection of drug administration regimens, reduces the risk of errors, optimizes the drug use process, and reduces unnecessary waste and complexity, especially for expensive and difficult-to-handle biopharmaceuticals.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
Technical Field
[0001] This invention relates to a computer-implemented method for determining a drug administration regimen for a subject, and a computing device for implementing the method. The method and device of this invention can be applied to determining administration regimens for drugs available in various dosage forms, which vary in dosage and / or concentration, particularly for drugs administered periodically over a longer period for preventative and / or therapeutic purposes. Background Technology
[0002] Many diseases and conditions require regular administration of medication for treatment and / or prevention. Clinical trials typically determine the safe and effective dosage of a drug, as well as the amount and intervals at which these dosages can be achieved. These can also depend on one or more parameters associated with the patient, such as their weight, age, sex, etc. Different combinations of drug dosages and administration intervals may exist to meet the conditions set in the clinical trial. Furthermore, drugs can be available in a variety of different dosage forms to increase the flexibility of administration.
[0003] Typically, healthcare professionals select administration regimens that meet the criteria set in clinical trials and are suitable for a particular patient. This can be a complex task, and the selection of a particular regimen can therefore lead to avoidable inconvenience and / or costs for the patient. These can be particularly problematic in cases of high-value products requiring long-term administration and / or administration that is relatively complex (e.g., by injection). Therefore, there is an unmet need for means of determining a patient's administration regimen, where choosing among multiple possibilities is not easily resolved. Simple tools exist that calculate the amount of medication to be administered based on the patient's weight and the relationship between weight and the required dosage. These tools reduce the risk of error in calculating the dosage. However, given the high practical impact of selecting a patient's administration regimen, there remains a need in the art for more efficient and accurate methods to determine a patient's administration regimen. Summary of the Invention
[0004] The inventors of this invention have developed a novel device and method for determining a drug administration regimen for a subject, wherein the drug is available in at least two different dosage forms, and the choice of administration regimen affects at least two different criteria. The method and device stem from the finding that, in such cases, suboptimal administration regimens may often be chosen by healthcare practitioners, and the complexity of the problem in selecting an appropriate administration regimen may far exceed the mental capacity of the healthcare practitioner responsible for this task. The inventors of this invention have recognized that this can be explained, at least in part, by the observation that the number of possible administration regimens falling within the limits set by clinical trials can grow exponentially, and the choice of combinations may have non-intuitive consequences for a set of criteria relevant to the patient.
[0005] A first aspect of the invention therefore provides a computing device including a processor and a memory, wherein the computing device is configured to determine a drug administration regimen for a subject by means of the following steps: receiving a value of at least one parameter associated with the subject; determining, at least in part, the amount of drug (A) to be administered to the subject per basic time period (t) based on the value of at least one parameter associated with the subject. t The drug is available in at least two different dosage forms (D1, D2), the at least two different dosage forms differing in the total amount and / or concentration of drug in the dosage form dose; all minimum combinations of the at least two different dosage forms (A) are calculated. t [D1,D2,D1D2]), the minimum combination can be used to achieve the amount of drug (A) to be administered to the subject. t The minimum combination is defined as achieving or exceeding the drug amount (A) by using the minimum number of doses of each dosage form in the dosage form combination (D1, D2, D1D2). t ) combination; select the combination (A) t [D1,D2,D1D2]) at least satisfies the first and second criteria; and outputs a subset of the selected combinations as one or more optimal administration regimens for the subject.
[0006] The inventors of this invention have recognized that multiple combinations of the at least two dosage forms can be frequently used to administer a certain amount of drug, and that, according to the prior art, not all of these combinations are considered. The inventors of this invention have further recognized that, by defining the concept of a minimum combination and calculating all such minimum combinations for automatic evaluation and selection, it is possible to calculate all possible combinations useful for evaluation.
[0007] Calculate all minimum combinations (A) of the at least two different dosage forms. t [D1,D2,D1D2])(The minimum combination can be used to achieve the amount of drug (A) to be administered to the subject. t This may include: (a) calculating the amount of drug to be administered to the subject (A) t (a) the minimum number of doses for each dosage form (single-dose combination); and (b) starting with each dosage form, calculating the amount of drug required to be administered to the subject (A). t The minimum number of doses required for each other dosage form, in combination with increasing the number of doses of the starting dosage form below the number obtained in (a). Where three or more dosage forms are available, calculating all minimum combinations may further include: (c) starting with each dosage form, calculating the amount of drug to be administered to the subject (A) tThe minimum number of doses required for each other dosage form is determined by combining the following approach: increasing the number of doses for the starting dosage form and then increasing the number of doses for each other dosage form in turn.
[0008] This article also provides a computer-implemented method for determining a drug administration regimen for a subject, the method comprising: receiving a value of at least one parameter associated with the subject; and determining, at least in part, the amount of drug (A) to be administered to the subject per basic time period (t) based on the value of at least one parameter associated with the subject. t The drug is available in at least two different dosage forms (D1, D2), the at least two different dosage forms differing in the total amount and / or concentration of drug in the dosage form dose; all minimum combinations of the at least two different dosage forms (A) are calculated. t [D1,D2,D1D2]), the minimum combination can be used to achieve the amount of drug (A) to be administered to the subject. t The minimum combination is defined as the minimum number of doses of each dosage form in the combination (D1, D2, D1D2) that reaches or exceeds the amount of drug to be administered to the subject (A). t ) combination; select the combination (A) t [D1,D2,D1D2]) at least satisfies the first and second criteria; and outputs a subset of the selected combinations as one or more optimal administration regimens for the subject.
[0009] Any feature of the methods described herein applies equally to computing devices configured to implement these methods. Similarly, any of the features of computing devices described herein can be applied to the methods described herein, where the computing device is configured to implement the methods.
[0010] In the context of this disclosure, a drug is one or more active ingredients administered to a subject for therapeutic or prophylactic purposes. A dosage form is a pharmaceutical preparation of a drug, each dose of which comprises a certain amount of the drug and optional excipients. Where excipients are included, the concentration of the drug in the dosage form may vary. Regardless of whether excipients are included, the total amount of drug in each dose of the dosage form may vary. Dosage forms can be single pills, tablets, capsules, vials of solution, or any other individual dose formulated according to the dosage form.
[0011] The apparatus and methods disclosed herein may be particularly advantageous in that at least one dosage form is a single-use dosage form. A single-use dosage form is one in which each dose can only be used for a single administration. Once a dose of a single-use dosage form has been at least partially consumed as part of a single administration, the remaining dose is lost and cannot be used for subsequent administrations. For example, a dose of a single-use dosage form may be a vial containing a sterile solution, or any other dosage form that is sterile before consumption, and in which the consumption of a partial dose impairs the sterility of the remaining dose. Similarly, a single-use dosage form may be any dosage form in which the consumption of a portion of the dose form would impair the properties of the remaining dose. This property may relate to safety (e.g., contamination, the generation of drug-derived forms, etc.) or efficacy (e.g., drug degradation). For example, a dosage form may contain components that oxidize or otherwise degrade upon exposure to air, and in which any remaining portion of the dose may be exposed to air during or after the consumption of a partial dose. When at least one dosage form is a single-use dosage form, the selection of which combination of dosage forms should be used may be particularly important, as different combinations may be associated with different amounts of loss (the remaining portion of the dose after partial consumption).
[0012] This drug may be a biopharmaceutical. In one embodiment, the drug is a peptide or protein. For example, the drug may consist of or contain antibodies. In one embodiment, the drug is an antibody as described in EP2644698B1, which is incorporated herein by reference. In one embodiment, the drug is emicizumab (commercially available as HEMLIBRA). The apparatus and methods described in this disclosure may be particularly advantageous in the case of biopharmaceuticals, which can be expensive and difficult to manufacture. Furthermore, biopharmaceuticals may have relatively short shelf lives and / or may only be available in single-use dosage forms. Therefore, optimization of administration parameters may be especially important for these types of products.
[0013] The apparatus and method of this disclosure are particularly advantageous when the drug is available in at least two different dosage forms (D1, D2) (different in drug concentration at the dosage of each dosage form). In fact, in such cases, selecting a suitable combination of dosage forms may be particularly difficult without the invention. Furthermore, the apparatus and method of this disclosure can be particularly advantageous when the drug is administered at regular intervals over a longer period of time. In fact, when the drug is administered over a longer period of time, it is particularly important to minimize the inconvenience and disadvantages associated with drug administration. A longer period of time can refer to a period during which multiple administrations of the drug are required to achieve a drug-related therapeutic or preventative effect. For example, treatment for drug-related preventative effects may require maintaining a minimum concentration of the drug in the patient's body (e.g., in plasma) for a predetermined period of time, thus requiring multiple separate administrations of the drug within said period. In some cases, said period of time may be the lifespan of the subject. In an embodiment, the drug is administered for the daily prevention of a disease or condition. In an embodiment, said condition is hemophilia and / or bleeding disorders. Furthermore, the subject can be a human or animal subject. Typically, the subject can be a human subject.
[0014] The methods and apparatus disclosed herein are not limited to the number of different dosage forms considered in the steps described herein, as long as multiple dosage forms (i.e., at least two dosage forms) are used. Specifically, the drug can be obtained in three dosage forms (D1, D2, D3), four dosage forms (D1, D2, D3, D4), five dosage forms (D1, D2, D3, D4, D5), or six dosage forms (D1, D2, D3, D4, D5, D6). At least two of the two, three, four, five, or six dosage forms may differ from each other in drug concentration at the dosage of the dosage form.
[0015] In the context of this disclosure, a subset may not be a strictly (actual) subset, but may include all combinations in the set. For example, this may occur when all combinations in the set are equal, as the evaluation is performed against the criteria used for selection.
[0016] Select the combination (A) t A subset of [D1,D2,D1D2] that satisfies at least the first and second criteria may include: selecting the combination (A) according to the first criterion. tThe first subset of [D1, D2, D1D2]) and a second subset of the combinations selected from the first subset according to a second criterion different from the first criterion. Therefore, outputting a subset of the selected combinations as one or more optimal administration options for the subject may include outputting the last selected subset of combinations as one or more optimal administration options for the subject. Furthermore, selecting a subset of combinations according to a criterion may include ranking the combinations according to the criterion and selecting all combinations with the best ranking. Implementation of successive selection based on subsets (i.e., hierarchical or nested application of criteria) can be particularly simple and efficient. Moreover, implementations using ranking to select subsets of combinations can make it possible to track unselected combinations, since the ranked list of combinations generated in the first selection can be used as a starting point for a second selection—for example, by ranking the combinations according to a second criterion within a ranking based on a first criterion.
[0017] The methods and apparatus disclosed herein do not limit the number of other criteria for selecting a contiguous subset of combinations. Therefore, the selection of combinations (A) t A subset of [D1,D2,D1D2] that satisfies at least the first and second criteria may include: selecting a combined subset that satisfies the first, second, and third criteria, the first, second, third, and fourth criteria, etc. Specifically, the computing device may also be configured to select a third (fourth, fifth, etc.) subset of the combination from the second (third, fourth, etc.) subset according to a third (fourth, fifth, etc.) criterion. In this case, the last selected subset output will be the third (fourth, fifth, etc.) subset. Similarly, the method of this disclosure may further include the steps of: selecting a subset from the previously selected subset according to a further criterion, and outputting the last of those consecutively selected subsets. In the context of this disclosure, a second criterion is a criterion different from the first criterion, a third criterion is a criterion different from the first and second criters, etc.
[0018] In the implementation, the amount of medication to be administered per basic time period (t) is provided as an input to the method described herein, as a function of one or more parameters associated with the subject. These may be stored in memory and retrieved by the processor before the method begins, or received by the processor as a value of at least one parameter associated with the subject. Furthermore, these may be provided as one or more mathematical relationships linking one or more parameters associated with the subject to the amount of medication to be administered per basic time period (t). The at least one parameter may include the subject's weight and the amount of medication (A) to be administered to the subject within each basic time period (t). tThe amount of drug to be administered to the subject can be based, at least in part, on values received regarding the subject's weight. The relationship between the amount of drug to be administered per baseline period (e.g., daily, weekly, or monthly) and the subject's weight can be provided as an output of the clinical trial, and these relationships can be used by the method of the present invention to automatically determine the amount of drug to be administered to the subject. For example, the amount of drug per kilogram (patient's weight) per baseline period can be provided as input to the method described herein. Therefore, the amount of drug to be administered to the subject per baseline period (t) (A) is determined, at least in part, based on the subject's weight. t The method may include multiplying the subject's weight by a pre-set (i.e., predetermined) amount of medication per basic time period (t). Furthermore, multiple such pre-set amounts per kilogram of medication per basic time period may be provided as input to the method, wherein the selection of such amounts depends on the value of another parameter associated with the patient (e.g., gender, age, disease severity / stage, etc.). In an embodiment, the at least one parameter is the subject's weight, and one or more parameters associated with the subject are further received. These may be selected from the group consisting of: subject age, subject gender, disease-related parameters, and treatment-related parameters. Disease-related parameters may be indications of disease severity, identity, stage, co-occurrence of another disease or condition, etc. Treatment-related parameters may be indications of another treatment the subject is currently undergoing or has already undergone. Therefore, the computing device may be configured to select a relationship between the subject's weight and the amount of medication to be administered per basic time period based on the value of the received at least one parameter (e.g., selected from a set of relationships stored in memory), and to calculate the amount of medication to be administered per basic time period according to the selected relationship using the received value of the subject's weight. For example, the amount of drug (A) to be administered to the subject per baseline time period (t) is determined based at least on the subject's weight and further parameters associated with the subject. t The processor may retrieve a selected preset amount of drug per basic time period (t) from memory, which depends on the value of at least one other parameter associated with the subject, and multiply the subject's weight by the selected preset amount of drug per basic time period (t).
[0019] The inventors also recognized that, in some cases, a suitable administration regimen can be based on one of multiple time intervals between administrations. In these cases, more possibilities need to be considered, which further increases the complexity of the problem, but also further increases the potential to identify particularly advantageous administration regimens. To accommodate and utilize this possibility, the computing device can also be configured to calculate the amount of drug (A) to be administered to the subject for one or more multiples (n) of the basic time period (t). n1t A n2t); and calculations for each of the basic time periods (t) for the plurality of multiples (n) can be used to achieve the amount of drug (A) to be administered to the subject. n1t A n2t All minimum combinations of at least two different dosage forms.
[0020] In an implementation, one or more suitable intervals between administrations (e.g., the maximum suitable interval between administrations) are provided as inputs to the method described herein. These may be stored in memory and retrieved by the processor before the method begins, or received by the processor as values of at least one parameter associated with the subject. One or more suitable intervals may be used to define a base period (t) of one or more multiples (n) suitable for the method disclosed herein. For example, one or more amounts of drug to be administered per kilogram per week may be provided in combination with a maximum suitable interval of 4 weeks. In an implementation, the computing device is also configured to determine that the base period (t) of the multiple (n) is a divisor of the base period (t) of a specific multiple (n), where the specific multiple corresponds to a preset maximum interval between administrations. Advantageously, this means that the computing device can be able to automatically identify alternative dosing regimens within preset boundaries (e.g., boundaries that may have been previously set by clinical trials).
[0021] In the implementation, the computing device is also configured to obtain one or more multiples (n) of the basic time period (t), either by receiving them as further parameters associated with the subject or by retrieving them from memory. Similarly, the method described herein may further include obtaining one or more multiples (n) of the basic time period (t), either by receiving them as another parameter associated with the subject or by using one or more predetermined multiples (n) of the basic time period (t). This can be particularly useful when strict adherence to administration intervals determined, for example, from clinical trials is recommended for any reason, such as safety, regulatory, or practical considerations related to administration, such as the availability of trained personnel.
[0022] In some cases, a drug is administered to a subject in multiple phases that together form a treatment process, where the administration regimen may differ between the phases. In such cases, it may be necessary to determine two potentially different administration regimens for each subject, which can further complicate the task of healthcare practitioners and may increase the risk of errors or the selection of suboptimal administration regimens. The apparatus and methods of this disclosure are advantageously capable of handling these situations. For example, the drug may be administered according to a first administration regimen during a first phase, which may be referred to as a “loading phase.” After the loading phase, the drug may be administered according to a second administration regimen, which may be referred to as a “maintenance phase.” One or more pre-defined amounts of drug (A) to be administered to the subject per basic time period (t). t One or more suitable intervals between administration and / or administration may vary between different phases. In an embodiment, the computing device may be configured to implement each step of the method described herein for one or more of a plurality of phases that together form a treatment process. For example, the computing device may be configured to determine the amount of drug (A) to be administered to the subject within each baseline time period (t). t The computer can also be configured to calculate all minimal combinations of the basic time periods (t) and any multiples (n) to be used, based on preset values for a first phase (e.g., a loading phase) and preset values for a second phase (e.g., a maintenance phase). The computer can also be configured to select a subset of these combinations for use in the first and second phases, respectively. For each phase in the first and second phases, the selected subset can be output together or separately. Alternatively, the computer can receive a selection of the treatment phase as input, based on which the amount of drug (A) to be administered to the subject per basic time period (t) can be determined. t Select a preset value for the appropriate interval between application and / or application.
[0023] Some steps of the method of this disclosure (and corresponding steps to which the device of this disclosure is configured to implement) may be performed before receiving the value of at least one parameter associated with the subject. For example, for a predefined set of values of the parameter associated with the subject, the amount (A) of the one or more drugs to be administered to the subject. t A nt ), and optionally, the minimum combination that can be used to achieve these quantities can be pre-calculated (e.g., calculated by a processor and stored in memory). In some such embodiments, the computing device can be configured to calculate the amount of drug (A) that can be used to achieve a predetermined set of drug amounts to be administered to the subject. t A ntEach of the at least two different dosage forms in the above-mentioned minimum combinations. The computing device may also be configured to, upon receiving a value of at least one parameter associated with the subject, determine, at least in part, the amount of drug (A) to be administered to the subject per basic time period (t). t ), in the pre-calculated amount of drug to be administered (A t A nt Identify the closest total drug amount (A) from the set of ) t A nt ), and select the closest drug amount (A) from the pre-calculated combinations that can be used to achieve identification. t A nt A subset of the combination of said at least one parameter. Alternatively, the computing device may be configured to determine, at least in part, the amount of drug (A) to be administered to the subject in each basic time period (t) based on a predetermined set of values of said at least one parameter (such as, for example, the subject's weight). t ), and calculate the amount of drug (A) that can be used to achieve the result determined from a predetermined set of values for at least one parameter. t A nt Each of the at least two different dosage forms in the above-mentioned combinations. The computing device may also be configured to, upon receiving a value of at least one parameter associated with the subject, identify the closest value in the predetermined set of values for the at least one parameter, and select from pre-calculated combinations the amount of drug (A) that can be used to achieve the amount corresponding to the identified closest value. t A subset of the combination of ). Similarly, the computing device can also be configured to calculate the total amount of drug to be administered (A) upon receiving a value of at least one parameter associated with the subject. t A nt ), in the pre-calculated amount of drug to be administered (A t A nt Select the closest required dosage of drug from the set of (A) t A nt ), and select the closest drug amount (A) from the pre-calculated combinations that can be used to achieve identification. t A nt A subset of combinations. Pre-compiling combinations allows for extensive checks on combinations, both automatically and / or manually, before they are used to generate recommendations for users. Furthermore, pre-compiling combinations increases the speed at which output is provided to the user upon receiving a request that includes a value for at least one parameter associated with the subject.
[0024] As used herein, the term "user" refers to a user of the methods and apparatus of this disclosure. The user may be the subject themselves, or a person using the methods and apparatus of this disclosure to determine an administration regimen for the subject. In the latter case, the user may be a healthcare professional.
[0025] In an alternative implementation, the amount of drug (A) to be administered to the subject within each basic time period (t) is determined. t The steps, and the calculation of the amount of drug available to achieve the required administration (A) t The steps for all minimal combinations are performed after receiving the value of at least one parameter associated with the subject. Calculating combinations upon receiving information about the subject may not require making any assumptions about the value of the at least one parameter to be used, and therefore may offer increased flexibility and accuracy. For example, in an embodiment where the at least one parameter includes the subject's weight, the exact weight can be used instead of the closest weight value from the set used to pre-calculate combinations.
[0026] The selection of the combination subset can be performed individually for the base time interval (t) and the base time interval (t) for each multiple (n), or jointly for the base time interval (t) and the base time interval (t) for all the multiples (n). When the selection is performed individually, the output (final) selected combination subset may include a subset of the (final) selected combinations of the base time interval (t) and the base time interval (t) for each multiple (n). In other words, one or more optimal application schemes can be provided for each of the different application intervals (t) that have been considered. This can advantageously present the user with the optimal solution for each application interval they might want to use, whereby the user can then select the most convenient application interval while knowing that they will use the optimal scheme for that particular application interval. In some such embodiments, the computing device is configured to output an indication of which selected application scheme is best within the selected subset of the base time interval (t) and the base time interval for each multiple (n) according to one of the criteria (preferably the first criterion). This can advantageously enable users to select a convenient application interval based on their preferences and knowledge of whether certain application intervals allow for the selection of a more advantageous application scheme. For example, when multiple application intervals are possible, it may not be immediately apparent that some of these application intervals cannot be selected without sacrificing the performance of one of the criteria that the user might be interested in. The methods and apparatus of this disclosure can address this situation by outputting the application scheme that is optimal for each application interval while also indicating whether these "individually optimal" application schemes (i.e., the optimal scheme for each application interval) are "globally optimal" (i.e., the optimal scheme among all schemes considered).
[0027] The selection of a criterion for any of the first, second, third, etc., choices can each be received as a value of one or more further parameters associated with the subject. For example, a criterion used as the first criterion can be received from the user. Second and optional subsequent criteria can be selected by the user in a similar manner, or default values can be used (e.g., default criteria stored in memory). Furthermore, default values for each of the second and subsequent criteria can be automatically selected based on the selection received for the first criterion. Further, the selection of the criterion can come from a predetermined set of criteria. For example, the method may include: providing a predetermined set of criteria to the user; and receiving a selection of one or more criteria from the predetermined set of criteria as a value of a further parameter associated with the subject.
[0028] Selecting a subset of combinations that meets the first / second / third / etc. criteria may include calculating the value of a parameter associated with each combination and selecting combinations that minimize or maximize the value of the calculated parameter. The combination that minimizes / maximizes the value of the calculated parameter may be a combination associated with the lowest / highest value of the calculated parameter in the set of combinations from which the subset is selected. This selection may include some tolerances such that combinations associated with parameter values within a predetermined distance of the lowest / highest value of the parameter in the set of combinations may be selected to be included in the subset that minimizes / maximizes the value of that parameter. For example, the value of the parameter associated with a combination may include losses associated with the combination, the number of physical application steps required to apply the combination, the number of physical preparation steps associated with applying the combination, or any combination or derivative thereof.
[0029] In an implementation scheme, the method includes calculating the loss (W) associated with the dosage form combination. t [D1,D2,D1D2];W n1t [D1,D2,D1D2];W n2t [D1,D2,D1D2]) represents the total amount of drug in the dosage form combination and the amount of drug to be administered to the subject (A). t A n1t A n2tThe method may further include calculating the total loss as a loss per time period. Calculating the total loss (loss per time period) may include calculating the loss for each base time period t. This can be done by dividing the loss for each combination by its corresponding multiple (n), where for combinations corresponding to base time periods (t), n = 1. In other embodiments, calculating the total loss (loss per time period) includes calculating the total loss (n) within the time period corresponding to the least common multiple of the multiples. Losses associated with the administration regimen may be a particularly useful parameter when the drug is expensive, difficult to obtain, and / or difficult to dispose of residues. Furthermore, tracking the loss of drug amounts may be particularly advantageous when some dosage forms have different concentrations. In practice, in such cases, even if the amount of dosage form being used according to each administration regimen can be determined, it may be unclear which administration regimen is associated with the lowest loss. Furthermore, calculating the total loss (loss for each comparable time period, whether considering base time periods or the least common multiple of different multiples n) may be particularly advantageous because it enables the determination of administration regimens optimized compared to repeated administration. This may not be immediately apparent from the perspective of parameters for a single administration, and may be particularly advantageous for drugs administered over a longer period. Therefore, in an implementation, one of the criteria for selecting a subset is the value of the total loss (loss per period) associated with each combination, and the selected combinations are those that minimize this parameter.
[0030] Alternatively, or in addition to calculating losses, the total number of physical administration steps required to administer the combination can be calculated, and this can be used as one of the criteria for selecting a subset of the combination. Calculating the total number of physical administration steps required to administer the combination may include calculating the minimum number of physical administration steps that can be used to administer the combination and satisfy one or more rules selected from: a preset maximum drug amount for each physical administration step, a preset maximum dosage form amount for each physical administration step, and restrictions on dosage form combinations that differ in concentration within a single physical administration step. Furthermore, the rules for the preset amount of drug / dosage form for each physical administration step may be applied differently depending on the precision required to administer a specific amount. For example, an amount specified with a specific precision may be associated with a different preset maximum drug / dosage form amount compared to an amount specified with another lower precision. Each of these rules may be predetermined (e.g., stored in memory) or may be received as one or more further parameters associated with the subject. Furthermore, the selection of one or more such predetermined rules may be based on the values of one or more parameters associated with the subject. For example, two or more preset maximum dosage form amounts may be obtained for each physical administration step, and the selection of one of these amounts may depend on parameters such as the subject's weight, the subject's age, disease-related parameters, etc. The number of physical application steps required for administration can be a particularly useful parameter when medication is difficult to administer, causes pain, or is inconvenient to administer. Furthermore, the total number of physical application steps required for an administration combination may not be immediately apparent from the combination itself, especially when multiple rules must be considered in determining the number of individual physical application steps required for an administration combination. In such cases, automatically calculating the total number of steps required for administration and comparing combinations based on this can advantageously ensure that no intuitively preferred combination can be selected due to the complexity of factors to be considered when administering combinations. Therefore, in an implementation, one of the criteria for selecting a subset applies to the value of the total number of physical application steps associated with each combination, and the selected combinations are those that minimize this parameter.
[0031] The preset maximum amount of drug for each physical administration step can be defined as the weight of the drug or the number of drug units. The preset maximum amount of dosage form for each physical administration step can be defined as the weight of the dosage form or the volume of the dosage form. In embodiments, the dosage form is a liquid formulation. For example, the dosage form can be a solution, suspension, or any other type of liquid formulation. A single physical administration step of a liquid formulation can be a single injection of a volume of dosage form. In some embodiments, each single injection has a preset maximum volume selected from a group including two preset maximum volumes (V1, V2). In some embodiments, each single injection has a preset maximum volume selected from a group including three preset maximum volumes (V1, V2, V3). In some embodiments, the computing device is also configured to prioritize administration regimens that do not combine a single injection with different maximum volumes. For example, when calculating the number of physical administration steps associated with a combination, the computing device can be associated with the lowest possible number of combinations that do not use different maximum volumes. This may help reduce the number of different syringes used. In embodiments, a single physical administration step can be a single ingestion of a volume of dosage form, which is a liquid formulation. In some embodiments, a single physical administration step may be a unit of time required to administer a volume of a liquid dosage form using intravenous means such as infusion. In some embodiments, the dosage form is a solid (e.g., tablet, powder, etc.) or an encapsulated dosage form. In some such embodiments, a single physical administration step may be a single ingestion of a weight or volume of a dosage form or one or more capsules or tablets.
[0032] Alternatively, or in addition to calculating the losses and / or total number of physical application steps required to administer the combination, the total number of physical preparation steps required to administer the combination can be calculated. This can also be used as one of the criteria applied to selecting a subset of combinations. Calculating the total number of physical preparation steps required to administer the combination may include calculating the number of doses for each dosage form that makes up the combination. The number of physical preparation steps may be proportional to the number of doses for each dosage form, each dose which, for each administration, may have to be extracted from its packaging and optionally placed in a form suitable for administration (e.g., drawn into a syringe for injection, poured into a container for ingestion, etc.). The total number of physical application steps required to administer the combination may be particularly useful when considering situations where administration requires complex preparation steps that are prone to errors and / or losses. For example, when the doses of a dosage form must be placed in a form suitable for administration by heating, pouring, diluting, dissolving, etc., each such step may be associated with the risk of error, loss, contamination, etc. Furthermore, the number of preparation steps may not be the same as the number of administrations, as multi-dose dosage forms may be suitable for administration in combination. Similar to the number of administration steps, the number of preparation steps and the ways in which these combinations are compared may not be intuitive. Therefore, considering one or two of these parameters may have particular value. Therefore, in the implementation, one of the criteria for selecting a subset is the value of the total number of physical preparation steps associated with each combination, and the selected combinations are those that minimize this parameter.
[0033] In addition to the parameters used to evaluate the combinations based on criteria for selecting a subset of combinations, further information about each combination can be advantageously calculated and optionally output to the user. This may include one or more of the following: losses associated with the combination (as the amount of drug and / or dosage form, combined across dosage forms in the combination and / or combined separately for each dosage form in the combination); total losses associated with the combination (as the amount of drug and / or dosage form, combined across dosage forms in the combination and / or combined separately for each dosage form in the combination); the number of doses per dosage form; the total number of doses across dosage forms; the amount used from each dosage form (as the amount of drug and / or dosage form) and / or the amount used from each dose of each dosage form; the amount of each dosage form and / or each dose of each dosage form used for each physical application step; the number of physical application steps; any parameters of the materials required for application, such as, when the dosage form is a liquid formulation for injection, the volume of the injection device used for each physical application step, and / or the number of syringes to be used.
[0034] Furthermore, at least one of the above parameters can be calculated in at least two ways, and the results of these calculations can be compared to identify any inconsistencies. For example, the calculation device can be configured to calculate the total amount and total loss for each dosage form used, and compare the total loss and the total amount for each dosage form to check the compatibility of the amounts with the multiple dosage forms used. If an inconsistency is detected, a further warning or error may be generated.
[0035] In implementations, a user interface may be provided through which a user can input information including the value of at least one parameter associated with a subject. Similarly, outputting one or more optimal administration protocols may include providing the user with information identifying the one or more optimal administration protocols via the user interface. The user interface may be part of a computing device configured to implement the methods described herein, or it may be part of a second computing device configured to implement the methods described herein and configured to communicate with the second computing device. For example, the computing device according to this disclosure may be configured to communicate with the second computing device such that the computing device receiving the value of at least one parameter associated with a subject includes the computing device receiving information from the second computing device (which may have been input by the user via the user interface of the second computing device), and the computing device outputting one or more optimal administration protocols includes the computing device transmitting information identifying the one or more optimal administration protocols to the second computing device (the second computing device is able to provide the information to the user via the user interface of the second computing device). Implementations where the same computing device implements the methods described herein and receives input / provides output via the user interface of the computing device can advantageously perform all computations locally. Therefore, they may not need, for example, to be connected to a network to provide results, and may not need to share data across public networks. Conversely, implementations that decouple the computing device implementing the method from the computing device associated with the user interface advantageously allow the tools of this disclosure to be provided by a centrally maintained computing system (such as, for example, a server). The ability to centrally maintain the computing system implementing the method ensures that the method uses up-to-date information and that appropriate computing power is dedicated to performing the necessary calculations. Furthermore, such implementations can be more easily provided as cross-platform implementations because they can be provided as, for example, web applications rather than platform-specific applications.
[0036] Also provided is an apparatus for automatically determining a drug administration regimen for a subject, the apparatus including a processor and a memory, wherein the memory stores instructions that, when executed by the processor, cause the processor to perform the steps of the method described herein. Specifically, the instructions may cause the processor to: receive the value of at least one parameter associated with the subject; and determine, at least in part, the amount of drug (A) to be administered to the subject in each baseline time period (t) based on the value of the at least one parameter associated with the subject. t The drug is available in at least two different dosage forms (D1, D2), the at least two different dosage forms differing in total drug amount and / or drug concentration at the dosage form dose; all minimum combinations (At[D1,D2,D1D2]) of the at least two different dosage forms are calculated, the minimum combinations being capable of achieving the amount of drug (A) to be administered to the subject. t The minimum combination is defined as the minimum number of doses of each dosage form in the combination (D1, D2, D1D2) that reaches or exceeds the amount of drug to be administered to the subject (A). t ) combination; select the combination (A) t The device comprises at least a subset of [D1, D2, D1D2] that satisfies the first and second criteria; and outputs a subset of the selected combinations as one or more optimal administration regimens for the subject. The device may have any of the above features.
[0037] The device of this invention may include a server or a personal computing device. The personal computing device may be a mobile device, such as a mobile phone or a tablet computer.
[0038] According to another aspect, a computer-readable medium is provided, which records instructions that, when executed by a processor, cause the processor to perform the steps of the method described herein. Specifically, the instructions may cause the processor to: receive the value of at least one parameter associated with the subject; and determine, at least in part, the amount of drug (A) to be administered to the subject per basic time period (t) based on the value of the at least one parameter associated with the subject. t The drug is available in at least two different dosage forms (D1, D2), the at least two different dosage forms differing in the total amount and / or concentration of drug in the dosage form dose; all minimum combinations of the at least two different dosage forms (A) are calculated. t [D1,D2,D1D2]), the minimum combination can be used to achieve the amount of drug (A) to be administered to the subject. t The minimum combination is defined as the minimum number of individual doses of each dosage form in each combination (D1, D2, D1D2) that reaches or exceeds the amount of drug to be administered to the subject (A).t ) combination; select the combination (A) t [D1,D2,D1D2]) at least satisfies the first and second criteria; and outputs a subset of the selected combinations as one or more optimal administration regimens for the subject.
[0039] This article also provides a method for treating subjects with medication, the method comprising the following steps:
[0040] The drug administration regimen for the subject is determined automatically (e.g., by a processor) by the following steps: receiving the value of at least one parameter associated with the subject; determining the amount of drug (A) to be administered to the subject per basic time period (t) based at least in part on the value of at least one parameter associated with the subject. t The drug is available in at least two different dosage forms (D1, D2), the at least two different dosage forms differing in the total amount and / or concentration of drug in the dosage form dose; all minimum combinations of the at least two different dosage forms (A) are calculated. t [D1,D2,D1D2]), the minimum combination can be used to achieve the amount of drug (A) to be administered to the subject. t The minimum combination is defined as the minimum number of doses of each dosage form in the combination (D1, D2, D1D2) that reaches or exceeds the amount of drug to be administered to the subject (A). t ) combination; select the combination (A) t [D1,D2,D1D2]) at least satisfies the first and second criteria; and outputs a subset of the selected combinations as one or more optimal administration regimens for the subject;
[0041] And to treat the subject with the optimal administration regimen (or one of the optimal administration regimens) for the subject. Implementation of this aspect may include any features described with respect to any other aspect.
[0042] Furthermore, the present invention provides a computer program stored on a medium for cooperating with hardware to perform the following steps: receiving the value of at least one parameter associated with the subject; determining, at least in part, the amount of drug (A) to be administered to the subject per basic time period (t) based on the value of at least one parameter associated with the subject. t The drug is available in at least two different dosage forms (D1, D2), the at least two different dosage forms differing in the total amount and / or concentration of drug in the dosage form dose; all minimum combinations of the at least two different dosage forms (A) are calculated. t[D1,D2,D1D2]), the minimum combination can be used to achieve the amount of drug (A) to be administered to the subject. t The minimum combination is defined as the minimum number of individual doses of each dosage form in the combination (D1, D2, D1D2) that reaches or exceeds the amount of drug to be administered to the subject (A). t ) combination; select the combination (A) t [D1,D2,D1D2]) at least satisfies the first and second criteria; and outputs a subset of the selected combinations as one or more optimal administration regimens for the subject. Attached Figure Description
[0043] Figure 1 An exemplary computing system in which embodiments of the present invention can be used is shown.
[0044] Figure 2 This is a flowchart illustrating a method for determining the drug administration regimen for a subject.
[0045] Figure 3 The main screen shows an exemplary implementation of a user interface for determining a drug administration regimen for a subject.
[0046] Figure 4 A results screen is shown as an exemplary implementation of a user interface for determining a drug administration regimen for a subject.
[0047] Figure 5 A dose details interface is shown as an exemplary implementation of a user interface for determining a drug administration regimen for a subject.
[0048] Figure 6 An exemplary implementation of the injection details interface of a user interface for determining a drug administration regimen for a subject is shown.
[0049] The accompanying drawings, which illustrate embodiments of the invention, should not be construed as limiting the scope of the invention. Where appropriate, the same reference numerals are used in different drawings to denote the same structural features of the illustrated embodiments. Detailed Implementation
[0050] Specific embodiments of the present invention will now be described with reference to the accompanying drawings.
[0051] Figure 1 An exemplary computing system in which embodiments of the present invention can be used is shown.
[0052] exist Figure 1A first computing device 1 is shown. The first computing device 1 forms part of a service provider computing system, and is therefore also referred to herein as a "service provider computing device". The first computing device 1 includes one or more processors 101 (e.g., a server) and one or more memories 102. The first computing device may further include multiple switches (not shown). A user (not shown) is equipped with a user computing device (also referred to herein as a "second computing device") 2. This can be a mobile computing device such as a mobile phone, personal computer, etc. The computing device 2 has at least one processor 202 and at least one memory 201, together providing at least one execution environment. Typically, mobile devices have firmware and applications running in at least one conventional execution environment (REE) with an operating system such as iOS, Android, or Windows. The computing device 2 is also equipped with means 203 for communicating with other components of the computing infrastructure, for example, via the public Internet 3. These means may include, for example, wireless telecommunications means for communicating with wireless telecommunications networks, local wireless communication means for communicating with the public Internet 3 using, for example, Wi-Fi technology, and / or wired communication interfaces for connecting to the public Internet 3. The second computing device 2 includes a user interface 204, which typically includes a display. The display 204 may be a touchscreen. Other types of user interfaces may be provided, such as speakers, keyboards, one or more buttons (not shown), etc. The second (user) computing device 2 can be connected to the first (service provider) computing device 1 via a network connection (e.g., via the public Internet 3).
[0053] In one embodiment, the first computing device 1 is configured to determine a drug administration regimen for a subject. In such an embodiment, memory 101 may store instructions that, when executed by processor 102, cause the processor to perform the steps of the method for determining a drug administration regimen for a subject as described herein. In such an embodiment, the first computing device 1 may be configured to receive information from user computing device 2, for example, via public internet 3. The first computing device 1 may also be configured to output information to user computing device 2, for example, via public internet 3. The information can then be displayed by user computing device 2, for example, using display 204. For example, processor 101 may include one or more servers, and the method may be implemented as a web page, a web application, or a progressive web application. In one embodiment, the method is implemented as a progressive web application running on the first computing device 1 and delivered to the second computing device 2 via public internet 3.
[0054] In other embodiments, the second computing device 2 is configured to determine a drug administration regimen for the subject. In such an embodiment, the memory 201 may store instructions that, when executed by the processor 202, cause the processor to perform the steps of the method for determining a drug administration regimen for the subject as described herein. In such an embodiment, the second computing device 1 may be configured to receive information via its user interface 204 when a user makes input. The second computing device 2 may also be configured to output information to the user, for example, via the user interface 204. In such an embodiment, the method may be implemented as an application running locally on the processor 202.
[0055] As those skilled in the art will understand, alternative implementations are possible. For example, processor 102 may be configured to perform the steps of a method as described herein for determining a drug administration regimen for a subject, and this method may be accessible via a local application that runs locally on the second computing device 2 and sends queries to the first computing device 1.
[0056] Figure 2 A general embodiment of a method for determining a drug administration regimen for a subject is shown. The method and apparatus of the present invention can be used in situations where the drug is available in at least two different dosage forms (D1, D2), wherein the at least two different dosage forms differ in the total amount and / or concentration of the drug in the dosage form dose.
[0057] In step 200, (e.g., via processor 102 or processor 202) the value of at least one parameter associated with the subject is received. The at least one parameter may be the subject's weight. In step 200, the values of one or more additional parameters may also be received. These may include one or more user preferences. User preferences may include, for example, selecting one or more criteria for determining the most suitable medication regimen for the subject, as will be discussed further below. User preferences may include selection of one or more administration frequencies (multiples of the basic duration of administration, as will be discussed further below). One or more further parameters associated with the subject may alternatively or additionally be selected from the group including: subject age, subject sex, disease-related parameters, and treatment-related parameters. Disease-related parameters may be indications of disease severity, identity, stage, co-occurrence of another disease or condition, etc. Treatment-related parameters may be indications of another treatment the subject is currently undergoing or has already undergone. The values of one or more parameters may be entered by the user at user interface 204 and transmitted to processor 102 / 202.
[0058] In step 210, the amount of drug (A) to be administered to the subject per basic time period (t) is determined at least in part based on the value of at least one parameter associated with the subject.t The amount of drug to be administered per basic time period (t) and one or more administration frequencies suitable for achieving the desired preventive or therapeutic effect of the drug can be predefined, for example, through clinical trials known in the art. In an implementation, a suitable (e.g., safe and effective) amount of drug to be administered per basic time period (t) is provided as an input to the method described herein as a function of one or more parameters associated with the subject. For example, these can be stored in memory 101 / 201. These can be provided as one or more mathematical relationships linking one or more parameters associated with the subject to a safe and effective amount of drug to be administered per basic time period (t). For example, a drug amount per kilogram (patient's weight) per basic time period can be provided as an input to the method described herein. Furthermore, multiple such drug amounts per kilogram per basic time period can be provided, wherein the selection of such amounts can depend on the value of another parameter associated with the patient (e.g., sex, age, disease severity / stage, etc.). Therefore, step 210 may include processor 102 / 202 retrieving from memory 101 / 201 a relationship linking one or more parameters associated with the subject to a (e.g., safe and effective) amount of drug to be administered per basic time period (t). Furthermore, when multiple such relationships are stored in memory 101 / 201, the selection of the retrieved relationship may depend on the value of at least one parameter received at step 200. Step 210 may further include the processor 102 / 202 applying a mathematical relationship to the value of at least one parameter received in step 200 (e.g., the subject's weight). Preferably, the at least one parameter includes the subject's weight, and the amount of drug (A) to be administered to the subject per basic time period (t) is determined at least in part based on the subject's weight. t The processor 102 / 202 multiplies the subject's weight by a pre-defined amount of medication for each baseline time period (t). The medication used in the baseline time period t may depend on the specific medication being used, such as the minimum interval between administrations evaluated in a clinical trial. In the implementation, the baseline time period t is selected from one day, one week, and one month. In the implementation, n is 2 and 4, and the baseline time period is one week.
[0059] Further optional step 220 may be performed, in which the amount of drug (A) to be administered to the subject is calculated for one or more multiples (n) of the basic time period (t). n1t A n2tThe one or more multiples (n) may be received in step 200 as a further parameter associated with the subject (i.e., as a user preference). In an embodiment, the values of the one or more multiples (n) may be stored in memory 101 / 201. These may be retrieved by processor 102 / 202 and used in step 220 (as a default value), or they may be used to check whether the one or more n values received in step 200 are compatible with the method. For example, the maximum value of n may be stored in memory, and processor 102 / 202 may verify in step 220 that any n value received in step 200 is a divisor of the maximum value stored in memory. The multiple n is typically an integer multiple, as administration schedules calculated in whole days, weeks, or months are more common. However, the method is not limited to this in principle. Further, the amount of drug A per basic period can be... t Multiplying each value of n by one or more multiples (n) for a basic time period (t), calculate the amount of drug (A) to be administered to the subject. n1t A n2t Alternatively, the amount of drug to be administered to the subject for one or more multiples (n) of a basic time period (t) can be calculated by retrieving from memory 101 / 201 the value of at least one parameter associated with the subject and the amount of drug to be administered per time period n*t. n1t A n2t For example, one or more amounts of medication to be administered per kilogram per week can be stored in memory in combination with the maximum appropriate interval of 4 weeks. These can be used to calculate the amount of medication to be administered to the subject weekly, every 2 weeks, or every 4 weeks, depending on the subject's weight. As those skilled in the art will understand, the mathematical relationship between the amount of medication and the value of at least one parameter associated with the subject may also be provided by the user prior to step 210 and stored in memory 101 / 201 for use in steps 210, 220.
[0060] In step 230, the amount of drug (A) that can be used to achieve the desired dosage for the subject is calculated. t The minimum combinations of at least two dosage forms of the drug (and each amount A) n1t A n2t (If applicable). For example, processor 102 / 202 can calculate all possible minimum combinations and store these combinations in memory 101 / 201. A minimum combination is defined as the minimum number of single doses of each dosage form used to achieve or exceed the drug amount (A) for each dosage form combination (D1, D2, D1D2). tCombinations of dosage forms (D1 and D2). For example, for a drug with two dosage forms, D1 and D2, combinations of the three types can achieve any dosage: D1 only, D2 only, and D1 and D2. If D2 contains half the amount of drug as D1 and requires a total dose of 2*D1, the minimum combinations are: 2*D1 (i.e., two doses of dosage form D1), 4*D2 (i.e., four doses of dosage form D2), and 1*D1+2*D2 (i.e., one dose of dosage form D1 and two doses of dosage form D2). In other words, for each of the three types of combinations, the minimum combination is the combination that includes the minimum number of doses required to achieve that amount while having the dosage forms in the set. For D1 alone, this is to achieve A t The minimum number of doses for D1. For D2 alone, this is to achieve A. t The minimum number of doses for D2. For D1+D2, these include both D1 and D2 (i.e., at least one D1 and one D2 must be used) and achieve A. t The minimum dose combination. For certain doses A t And some dosage forms D1, D2, may have multiple minimum combinations in the combination of different dosage forms (because, for example, some amounts A) t It can be 1*D1+2*D2 or 2*D1+1*D2). In the implementation, it depends on the quantity A. t Necessary, certain types of combinations may not be represented in the minimum combination calculated in step 230, because quantity A t Less than the amount of drug contained in at least one dosage form. For example, if A t If the amount of drug contained in dosage form D1 or D2 is less than that contained in a single dosage form, then the D1D2 combination may not be generated. In this embodiment, the amount of drug contained in each dosage form (D1, D2) can be stored in memory 101 / 201 and retrieved by processor 102 / 202. Alternatively, the amount of drug contained in each dosage form (D1, D2) can be provided by the user before processor 102 / 202 performs step 230.
[0061] In the implementation scheme, the drug is administered to the subject in multiple phases that collectively form a treatment process, wherein the administration regimen may differ between the phases. For example, the drug may be administered according to a first administration regimen during a first phase, which may be referred to as a “loading phase,” and after the loading phase, the drug may be administered according to a second administration regimen, which may be referred to as a “maintenance phase.” One or more doses (A) of drug to be administered to the subject per baseline time period (t). tOne or more suitable intervals between application and / or administration may vary between different treatment phases. In an embodiment, each of steps 210, 220, and 230 may be implemented for one or more of a plurality of phases that together form a treatment process. In an embodiment, the selection of a treatment phase may be received as a parameter in step 200, and steps 210, 220, and 230 may be implemented accordingly.
[0062] In steps 240, 250 (and 260, if applicable), select the combination (A). t [D1,D2,D1D2]) is a subset that satisfies at least the first and second criteria. In this particular implementation, in step 240, the combination (A) generated in step 230 is selected according to the first criterion. t [D1,D2,D1D2]-and A n1t [D1,D2,D1D2];A n2t A first subset of [D1, D2, D1D2], if applicable. For example, processors 102 / 202 may evaluate the combinations calculated at step 230 and stored in memory 101 / 201 against a first criterion, select a first subset of combinations based on the evaluation, and store the first subset in memory 101 / 201. Selecting a subset of combinations that satisfy the first criterion may include calculating the value of a parameter associated with the combination and selecting combinations that maximize or minimize the parameter. Alternatively, combinations with values higher or lower than a predetermined threshold for the calculated parameter may be selected. Furthermore, combinations with values within a certain distance of the maximum / minimum value among all combinations may be selected. As those skilled in the art will understand, depending on the combinations and criteria used, the subset may actually include all combinations, for example, where all combinations satisfy the criterion (e.g., because the value of the parameter is the same for all combinations, or within a certain distance of the minimum / maximum value of the parameter among all evaluated combinations). Selecting a subset of combinations may be performed, for example, by sorting the combinations according to the criterion and selecting all combinations with the joint best ranking. In an implementation that calculates combinations for one or more values of n (except n=1), the selection can be made separately for the base period (t) and the base period (t) for each multiple (n). Alternatively, the selection can be made jointly for the base period (t) and the base period (t) for each multiple (n).
[0063] In step 250, the combination (A) selected in step 240 is chosen according to the second criterion. t [D1,D2,D1D2] – and A n1t [D1,D2,D1D2];A n2tA second subset of the subset of [D1, D2, D1D2], if applicable. The selection of the second subset from the first subset can be performed as explained above with respect to step 240. For example, processor 102 / 202 can evaluate the combinations calculated at step 230 (or only the subset selected at step 240) and stored in memory 101 / 201 against a second criterion (e.g., by calculating the value of a second parameter associated with the combination) and stored in memory 101 / 201, select a second subset of the combinations from the first subset based on the evaluation, and store the second subset in memory 101 / 201.
[0064] In optional step 260, a third subset can be selected from the second subset according to a third criterion. The selection of the third subset from the second subset can be performed as explained above regarding step 240. For example, processor 102 / 202 can evaluate, against the third criterion, the combinations calculated in step 230 (or only the subset selected in step 240, or the subset selected in step 250) and stored in memory 101 / 201, select a third subset of the combinations in the second subset based on the evaluation, and store the third subset in memory 101 / 201. As those skilled in the art will understand, any number of other criteria can be used to hierarchically select subsets of previously selected subsets. For example, a fourth subset can be selected from the third subset using a fourth criterion, a fifth subset can be selected from the fourth subset using a fifth criterion, and so on.
[0065] In one implementation, the further parameters received at step 200 include a selected standard. In such an implementation, this standard can be combined with one or more preset further standards that can be stored in memory 101 / 201 as a first standard for selecting an application scheme. For example, a second standard and any further standards (if used) can be automatically selected based on the standard received at step 200. In other words, memory 101 / 201 can store a default standard to be used in combination with the selected first standard, and processor 102 or 202 can retrieve the value of this parameter from memory 101 / 201 based on the value received at step 200. Similarly, step 200 may include receiving at least two further parameters including a first standard and a second standard. These can be combined with a third standard that can be stored in memory 101 / 201 and set as a default parameter. Step 200 may also include receiving at least three further parameters, including a first standard, a second standard, and a third standard. In one implementation, a default selection can be stored in memory 201 / 101 for all standards including the first standard.
[0066] The parameters associated with a subset of combinations that can be calculated to select combinations may include one or more of the following: losses associated with the dosage form combination, total losses per time period, the total number of physical application steps required to administer the combination, and the total number of physical preparation steps required to administer the combination. The total losses per time period can be calculated as the total losses per base time period and / or the total losses (n) within a time period corresponding to the least common multiple of the multiples. The total losses per base time period can be calculated by dividing the losses of each combination by its corresponding multiple (n), where n = 1 for combinations corresponding to base time periods (t). The total losses within a time period corresponding to the least common multiple (n) can be calculated by multiplying the losses of each combination by the multiplier required to reach the least common multiple of the multiple n associated with the combination. For example, for n = 2 and n = 4, the least common multiple is 4, and in this embodiment, the total losses can be calculated over 4 base time periods. This can be achieved by multiplying the losses of each combination in the base time period by 4, and the losses of each combination in the base time period n = 2 by 2. The total number of physical application steps required to administer the combination can be calculated as the minimum number of physical application steps that can be used to administer the combination and satisfy one or more rules. The rules and any other parameters of dosage forms D1, D2 to which the rules must be applied can be stored in memory 101 / 201 and retrieved by processor 102 / 202 to calculate the total number of physical application steps. The total number of physical preparation steps required to administer the combination can be calculated as the number of doses for each dosage form constituting the combination. When multiple preparation steps are applicable to certain dosage forms, this can be stored as parameters of dosage forms D1, D2 in memory 101 / 201 and retrieved by processor 102 / 202 to calculate the total number of physical preparation steps by multiplying the number of doses for each dosage form by the corresponding number of physical preparation steps.
[0067] In step 270, based on the first and second (and optionally third or further criteria) criteria, the (final) selected subset of combinations is output as the one or more optimal administration regimens for the subject. In embodiments, outputting the optimal administration regimens may include processor 202 causing information identifying one or more optimal administration regimens to be displayed on user interface 204. For example, processor 102 may transmit information identifying one or more optimal administration regimens to processor 202, which may then display it on user interface 204. Alternatively, processor 202 may be able to perform at least some of the above calculations locally and thus selectively combine and output information identifying the selected combinations as the one or more optimal administration regimens. In embodiments, a single optimal administration regimen (i.e., a combination of dosage forms) may be output. In embodiments, multiple optimal administration regimens (i.e., combinations of dosage forms) may be output. In embodiments, a single optimal administration regimen (t) and a basic time period for each multiple (n) may be output over a basic time period. In embodiments that output multiple optimal administration regimens, an indication of which of the output administration regimens is optimal according to one of the criteria may also be output. For example, the multiple optimal administration regimens may be output along with an indication of which of these multiple optimal administration regimens optimizes the first criterion. For example, when the optimal application scheme is output separately for each multiple n, these may not all be optimal for all combinations of all application intervals. In such cases, it may be useful to include an indication of which of these is optimal according to a certain criterion (e.g., a first criterion).
[0068] The output combination includes information identifying the combination, including the identifiers and quantities of the dosage forms comprising the combination. If applicable, the information identifying the combination may further include the administration interval (t, n*t). This information is provided to the user via a user interface, or via a user interface to a user device, and subsequently to the user. The user interface may be provided as, for example, a webpage displayed on the user device. In such an implementation, the user can input information, for example, by typing or selecting items, causing the user device to retrieve the information from the server as a new webpage.
[0069] Additional parameters associated with the output administration regimen can also be calculated and optionally output in step 270. These parameters may include one or more of the following: losses associated with the combination, total losses associated with the combination, the amount to be used from each dosage form, the amount of each dosage form used for each physical administration step, etc. When the drug is a liquid formulation for injection, these parameters may further include the volume of the injection device (e.g., syringe) used for each physical administration step. Advantageously, at least one of the above parameters can be calculated in at least two ways, and the results of the calculations can be compared to ensure they are consistent. Furthermore, at least two of the above parameters can be calculated by processor 102 / 202 to check whether at least two values are consistent. For example, processor 102 / 202 can calculate the total amount and total loss of each dosage form used, and compare the total loss and the total amount of each dosage form to check that the amounts are compatible with the multiple dosage forms used.
[0070] As those skilled in the art will understand, the above general principles apply to situations where the drug is available in three or more dosage forms (e.g., four, five, or six dosage forms). For example, in the case where the drug has four different dosage forms (D1, D2, D3, D4), a minimum combination of 15 types can be considered: D1, D2, D3, D4, D1D2, D1D3, D1D4, D2D3, D2D4, D3D4, D1D2D3, D1D2D4, D2D3D4, D1D3D4, and D1D2D3D4. As mentioned above, depending on the required amount of drug A... t The amount of drug contained in each dosage form, and not all combinations of types will be shown. For example, if A t If the amount of drug in D4 is less than that in D4, then the minimum combination including D4 with any other dosage form will not be calculated. In an embodiment, any two of the three or more dosage forms may differ from the total amount of drug in the dose of the dosage form. Similarly, any two of the three or more dosage forms may differ in the drug concentration in the dose form. Furthermore, any two of the two or more dosage forms may differ in both the drug concentration and the total amount of drug in the dose of the dosage form.
[0071] Example
[0072] Exemplary methods for determining the drug administration regimen for a subject will now be described. The embodiments described here relate to the administration of the drug emicizumab, which is commercially available. (Roche Products Limited). Emicizumab is a humanized monoclonal modified immunoglobulin G4 (IgG4) antibody produced using recombinant DNA technology in mammalian Chinese hamster ovary (CHO) cells. Emicizumab is described in EP2644698B1, which is incorporated herein by reference. Emicizumab is a bispecific antibody that specifically binds to coagulation factors F.IX / F.IXa and FX, and substitutes for the cofactor function of coagulation factor F.VIII by promoting the activation of FX by F.IXa. This function is defective in patients with hemophilia A, leading to bleeding abnormalities. Emicizumab is available in four different dosage forms, all of which are subcutaneous solutions:
[0073] - Hemlibra 30mg: 1ml solution vial containing 30mg of emicizumab at a concentration of 30mg / ml; due to the color of the packaging, this dosage form is also referred to herein as the "sky blue vial";
[0074] - Hemlibra 60mg: 0.4ml vial containing 60mg of emicizumab at a concentration of 150mg / ml; this dosage form is also referred to as the "purple vial" in this document.
[0075] - Hemlibra 105mg: 0.7ml vial containing 105mg of emicizumab at a concentration of 150mg / ml; this dosage form is also referred to herein as the "green vial"; and
[0076] - Hemlibra 150mg: 1ml vial containing 150mg of emicizumab at a concentration of 150mg / ml; this dosage form is also referred to herein as the "brown vial".
[0077] Hemlibra is used for the daily prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) who have factor VIII inhibitors and in patients with severe hemophilia A (congenital factor VIII deficiency, FVIII < 1%) who do not have factor VIII inhibitors.
[0078] Clinical trials have determined that Hemlibra is suitable for all age groups and should be administered following a two-stage regimen, including:
[0079] - Loading phase: Recommended dose 3 mg / kg, administered once weekly for 4 weeks;
[0080] - Maintenance phase: The recommended dose is 1.5 mg / kg / week, with the lowest frequency of administration being once every 4 weeks (the maximum interval between two administrations is 4 weeks), that is, 1.5 mg / kg once a week, 3 mg / kg once every two weeks, or 6 mg / kg once every four weeks.
[0081] In this embodiment, further administration rules are provided, including combining two different concentrations of Hemlibra in the same syringe, with each injection not exceeding 2 ml, administered in 1 ml or 2-3 ml syringes, and when using a 1 ml syringe, the dosage should be accurate to two decimal places (in ml). Data from clinical trials stipulate that maintenance regimens (weekly, every 2 weeks, or every 4 weeks) should be selected for adherence support purposes, and the amount of emicizumab should be calculated accordingly as "patient weight (kg) x dose (1.5; 3 or 6 mg / kg) = total amount of emicizumab to be administered (mg)". An appropriate dose and volume should be selected based on the available vial concentration. Once a vial is selected, the total volume of Hemlibra can be calculated as "total amount of emicizumab to be administered (mg) ÷ vial concentration (mg / mL) = total volume of Hemlibra to be injected (mL)".
[0082] This leaves many options open and creates opportunities for errors, as the regimen supporting adherence may not be entirely independent of the choice of vial combination to be used. In fact, adherence can depend on factors such as the required number of injections, regimen-related attrition, and so on. Therefore, the inventors of this invention have recognized that the selection of an administration regimen should consider multiple variables, including in this embodiment: the frequency of administration in the maintenance regimen; the patient's weight; the different dosage forms available; limitations on administration (volume and combination of dosage forms); and criteria that may be patient-related, including (per administration and over four weeks) the amount of product attrition; (per administration) the required number of injections; and the number of physical steps required to prepare for administration (proportional to the number of vials drawn). Therefore, the inventors of this invention have designed a tool that takes all these variables into account to determine the patient's administration regimen.
[0083] In the specific implementation described here, the method takes the following as input:
[0084] - The pre-set dose multiplier (x mg / kg) for the loading phase (QL = 3 mg / kg), the maintenance phase regimen for weekly (Q1W = 1.5 mg / kg), bi-weekly (Q2W = 3 mg / kg), and bi-weekly (Q4W = 6 mg / kg);
[0085] - The concentration (C) of each of the four dosage forms (D1 = sky blue vial (SB), D2 = purple vial (P), D3 = turquoise vial (T), D4 = brown vial (B)) SB C P C T C B ) and volume (V SB V P V T V B ));
[0086] - The weight range for the administration regimen should be determined, for example, w = 3 to 150 kg, in increments of integers;
[0087] - Administration procedure rules, such as two possible syringe volumes V1 and V2, conditions under which a specific syringe volume cannot be used, and whether different vials / vials of different concentrations can be combined in the same syringe.
[0088] Then, the method performs three consecutive steps:
[0089] 1. Calculate the dosage: Total dose (mg) per body weight for each regimen (load, maintenance-weekly, maintenance-every-two-week, maintenance-every-four-week), where the load dose is the same as the maintenance-every-two-week dose (although the administration intervals are different);
[0090] 2. Calculate Combinations: For each total dose, generate all minimum combinations of dosage forms that can be used to achieve the total dose, and calculate the parameters for each minimum combination;
[0091] 3. Generate recommendations: For each weight, determine the combination of one or more criteria that minimizes the weight, and generate descriptions for these criteria.
[0092] These steps will be discussed in more detail below. In the embodiments discussed below, steps 1 through 3 are performed for weight ranges, and all combinations and recommendations are pre-calculated for each of these weights. Therefore, when a specific weight is entered via the user interface, recommendations can be easily extracted from the appropriate recommendation set. In other implementations not discussed in detail below, each of steps 1 through 3 is performed for a single specific weight. For example, steps 1 through 3 can be performed on the fly when a weight is received via the user interface. In this case, similar calculations to those discussed below also apply, although for a single weight instead of a list of weights.
[0093] In step 1, four total doses A are calculated for each body weight w = 3…150. L w t A w t A wn1t A w n2t Each of the following (where t = 1 week, n1 = 2, n2 = 4, and L refers to the loading phase dose):
[0094] A L w t =QL*w (Equation 1)
[0095] A w t =Q1W*w (Equation 2)
[0096] A w n1t =Q2W*w=Q1W*n1*w (Equation 3)
[0097] A w n2t =Q4W*w=Q1W*n2*w (Equation 4)
[0098] Step 1 yields a list of 441 total doses (147 different body weights, each with 3 different total doses) – because in this embodiment QL = Q²W. This list is considered the input for Step 2. In Step 2, all possible minimum combinations of four dosage forms that can be used to achieve each amount of drug represented in these 441 total doses are calculated. In particular, for each total dose (A... L w t A w t A w n1t A w n2t —Or, for better efficiency, for each different total dose represented in this list, to calculate the number of SB, P, T, and B vials (n) that make up the combination. SB n P n T (n), perform the following steps:
[0099] a. Sky blue as the dominant color combination
[0100] i. Only sky blue (A) w [SB]): Achieving dosage (A) w The minimum quantity of the sky-blue vials was calculated as follows:
[0101] n SB =round.up(A w / (C SB *V SB (Equation 5)
[0102] The `round.up()` function rounds the number between parentheses to the nearest integer.
[0103] ii. Sky blue and purple combination (A) w [SBP]): Cycle: 1 SB vial + Achieved dose (A w The minimum number of P vials; 2 SB vials + the minimum number of P vials to achieve the dose; and so on, until the number of SB vials reaches a point where no additional vials are needed to make up the total (at which point the number of SB vials is just below n calculated in step i). SB ), where for each SB vial, the quantity n SB The minimum quantity of vials P is calculated as follows:
[0104] n P =round.up((A w -1*(C SB *V SB )) / (C P *V P (Equation 6)
[0105] iii. A combination of sky blue and turquoise (A) w [SBT]): Cycle: 1 SB vial + Achieved dose (A w The minimum number of T vials; 2 SB vials + the minimum number of T vials to achieve the stated dose; and so on, until the number of SB vials reaches a point where no additional vials are needed to make up the total, where for each SB vial, the number of T vials is n. SB The minimum quantity of T vials is calculated as follows:
[0106] n T =round.up((A w -1*(C SB *V SB )) / (C T *V T (Equation 7)
[0107] iv. Sky blue and brown combination (A) w [SBB]): Cycle: 1 SB vial + Achieved dose (A w The minimum number of B vials; 2 SB vials + the minimum number of B vials to achieve the dose; and so on, until the number of SB vials reaches a point where no additional vials are needed to make up the total (i.e., n calculated in step i). SB ), where for each SB vial, the quantity n SB The minimum quantity of vial B is calculated as follows:
[0108] n B =round.up((Aw -1*(C SB *V SB )) / (C B *V B (Equation 8)
[0109] b. Repeat the process in a. for the purple-dominant combination.
[0110] c. Repeat the process in a. for the dominant cyan-green combination.
[0111] d. Repeat the process in a. for the brown dominant combination.
[0112] e. Calculate the combinations of 3 colors:
[0113] i. Dominated by sky blue, plus purple and turquoise (A) w [SBPT]): Loop: x = number of SB vials and y = number of P vials:
[0114] x = 1: The minimum number of 1 SB vial + 1 P vial + T vial to achieve the dosage; the minimum number of 1 SB vial + 2 P vials + T vials to achieve the dosage; and so on, until the total amount in 1 SB vial + y P vials exceeds the total amount A. w ;
[0115] x = 2: the minimum number of 2 SB vials + 1 P vial + T vials to achieve the dosage; the minimum number of 2 SB vials + 2 P vials + T vials to achieve the dosage; and so on, until the total number of 2 SB vials + y P vials exceeds the total number A. w ;
[0116] Wait until the total amount in x SB vials + 1 P vial exceeds the total amount A. w .
[0117] ii. Dominated by sky blue, with purple and brown (A) w [SBPB]) Repeat step i
[0118] iii. Dominated by sky blue, plus turquoise and purple (A) w [SBTP]) Repeat step i
[0119] iv. Predominantly sky blue, with hints of turquoise and brown (A) w [SBTB]) Repeat step i
[0120] v. Dominated by sky blue, with brown and purple (A) w [SBBP]) Repeat step i
[0121] vi. Predominantly sky blue, with brown and turquoise (A) w [SBBT]) Repeat step i
[0122] vii. Predominantly purple, with turquoise and sky blue (A) w [PTSB]) Repeat step i
[0123] viii. Predominantly purple, with hints of turquoise and brown (A) w [PTB]) Repeat step i
[0124] ix. is dominated by purple, with brown and sky blue as accents (A) w [PBSB]) Repeat step i
[0125] x. Predominantly purple, with brown and turquoise (A) w [PBT]) Repeat step i
[0126] xi. is dominated by cyan, with purple and sky blue (A) w [TPSB]) Repeat step i
[0127] xii. Predominantly turquoise, with purple and brown (A) w [TPB]) Repeat step i
[0128] xiii. Predominantly turquoise, with brown and sky blue (A) w [TBSB]) Repeat step i
[0129] xiv. Predominantly turquoise, with hints of brown and purple (A) w [TBP]) Repeat step i
[0130] xv. is dominated by brown, with purple and sky blue (A) w [BPSB]) Repeat step i
[0131] xvi. predominantly brown, with purple and turquoise (A) w [BPT]) Repeat step i
[0132] xvii. is predominantly brown, with hints of turquoise and sky blue (A). w [BTSB]) Repeat step i
[0133] xviii. Predominantly brown, with turquoise and purple (A) w [BTP]) Repeat step i
[0134] Step 2 also includes, for each combination, calculating at least the following parameters for each minimum combination: the total number of vials drawn (the total number of vials required), the amount of product drawn from each vial (in mg and ml), the loss of unused product per administration (in mg), and the number of injections required to administer the combination. The loss of unused product (in mg) can be calculated in several ways. For example, the total amount of drug in the combination can be calculated as follows:
[0135] Total(n SB ,n P ,n T ,n B )=(n SB *C SB *V SB )+(n P *C P *V P )+(n T *C T *V T )+(n B *C B *V B (Equation 9)
[0136] And for a specific quantity A w The combined loss W can be calculated as
[0137] W = Total(n) SB ,n P ,n T ,n B )-A w (Equation 10)
[0138] Alternatively, you can calculate the total amount (ml or mg) drawn from each vial and compare it to the total amount (ml or mg) that can be obtained from each vial.
[0139] The total amount drawn from each vial can be calculated as the total amount present in each vial, except for the last vial added. For the last vial added, the total amount drawn can be calculated to reach the required amount A. wThe volume required is the volume obtained by subtracting the amounts already provided by other vials. As those skilled in the art will understand, the specific order of the steps used to generate the combination is arbitrary, and any order can be used as long as all possible combinations are generated. Furthermore, the parameters for each combination can be calculated as each combination is generated, or a list of combinations can be generated and iterated to calculate each parameter. The number of injections used to administer the combination is calculated according to the rules regarding syringe volumes V1 and V2 described above, and the rules regarding vial / concentration combinations. In this embodiment, 1ml or 2ml syringes can be used, and sky-blue vials cannot be combined with any purple, turquoise, or brown vials. In this case, the number of injections can be calculated as follows:
[0140] -If using at least one sky-blue vial (n SB ≥1)
[0141] o Calculate the number of injections (V1 = 1 ml or V2 = 2 ml) necessary to determine the total amount of product contributed by the sky blue vial in the application combination;
[0142] o Calculate the number of injections (V1 = 1 ml or V2 = 2 ml) necessary to administer the total amount of product contributed by all other vials in the administration combination, and impose the restriction that any amount accurate to two decimal places (in ml) can only be administered using a 1 ml syringe—for example, by calculating the number of injections required to administer all complete vials and determining whether the remaining volume to be administered requires the use of a 1 ml syringe.
[0143] Add the four numbers above to generate three sub-combinations: a sub-combination using only V1 = 1 ml, a sub-combination using only V2 = 2 ml, and two sub-combinations using both volumes.
[0144] -If you don't use the light blue bottle (n SB =0): The number of injections required to calculate the total amount of product contributed by all other vials in the administration combination, with the additional restriction that any amount accurate to two decimal places (in ml) can only be administered using a 1 ml syringe.
[0145] -Filter combinations, and if necessary, retain only the following: combinations with the minimum injection volume, combinations using the smallest possible syringe, and / or combinations using only one type of syringe (i.e., one volume).
[0146] As a result of step 2, a data table is generated containing information and parameters for each of the 85,008 combinations. A subset of this table is shown in Table 1 below, which includes multiple example parameters for selecting possible combinations to achieve one of the four different total doses. In the illustrated embodiment, a table is obtained for each different amount A generated in step 1. wAll combinations and their parameters are listed. This table can be expanded to list every weight from w = 3…150 kg and four application schemes A. L w t A w t A w n1t A w n2t The table lists all combinations of each application regimen and its parameters. Alternatively, as mentioned above, the table generated in step 2 also lists all combinations of all four types of application regimens for each body weight.
[0147] When such an expanded table is generated (or when the table is initially generated in expanded form in step 2), the loss for each comparable period (e.g., 4 weeks) can also be calculated. In this example, the total loss for each comparable period is calculated by appropriately scaling the loss for each application, i.e., either by scaling the total dose (AA) for n1=2 and n2=4. w n1t A w n2t The losses of ) are divided by 2 and 4 respectively, or n=1 (i.e., A) w t ) and n1 = 2(A w n1t The total dose loss is multiplied by 4 and 2, respectively. The latter may be preferable because it may lead to a more intuitive measure of loss.
[0148] The method then proceeds to step 3, where recommendations are generated. In this example, recommendations are generated using three different criteria: the amount of waste over 4 weeks, the number of injections per administration, and the number of vial draws. Specifically, for each patient's weight w = 3…150 kg, the method generates a list of all evaluated administration regimens. The method then ranks each list in a nested / hierarchical manner according to the three criteria mentioned above (by ranking combinations according to the first criterion, then within each ranking, ranking combinations according to the second criterion, and within each of these rankings, ranking combinations according to the third criterion and / or marking the best-ranked combination within each ranking). Furthermore, in this embodiment, this is done according to two different hierarchical structures.
[0149] The first level prioritizes minimizing losses for each comparable period (e.g., total losses over 4 weeks), so the combinations in the table are ranked according to total losses. Then, the best-ranked (i.e., lowest-loss) combinations are ranked again based on the number of injections per administration. Next, the best-ranked (i.e., lowest-injection) combinations are ranked based on the number of vial extractions. Finally, the best-ranked combinations (i.e., the best-ranked combination among the highest-ranked combinations (based on total losses) (based on injections) (based on vial extractions)) are stored in the "Minimum Loss Recommendation" list. In this embodiment, each ranking is performed separately for each of the four administration protocols (load, maintenance-weekly, maintenance-every two weeks, and maintenance-four times per week), and the best-ranked combination for each of these is output to the "Minimum Loss Recommendation" list. If two or more combinations have the same ranking across all three criteria, all of these combinations can be output to the "Minimum Loss Recommendation" list, or one can be chosen arbitrarily. Furthermore, combinations in the "Minimum Loss Recommendation" list are flagged if they have (i) the same total loss as the overall minimum total loss combination (across all application regimen categories) and (ii) the same number of injections as the overall minimum number of injections combination (across all application regimen categories). Alternatively, nested ranking can be performed jointly over all maintenance regimens. In this case, only the option with the optimal value is output, which may not include solutions for each different category of maintenance regimen.
[0150] The second-level structure prioritizes minimizing the number of injections, thus ranking the combinations in the table based on the number of injections per administration. The best-ranked combination (i.e., the lowest number of injections) is then ranked again based on the number of vial draws per administration. The best-ranked combinations (i.e., the lowest number of vial draws) are then ranked based on the lowest total loss. The final best-ranked combinations are then stored in the "Minimum Injection Recommendation" list. In this embodiment, each ranking is performed separately for each of the four administration protocols (load, maintenance-weekly, maintenance-every two weeks, and maintenance-four times a week), and the best-ranked combination is output to the "Minimum Injection Recommendation" list for each of these. If two or more combinations have the same ranking across all three criteria, all of these combinations can be output to the "Minimum Injection Recommendation" list, or one can be chosen arbitrarily. However, combinations in the "Minimum Injection Recommendation" list are flagged if they have (i) the same total loss as the overall lowest total loss combination (across all administration protocol categories) and (ii) the same number of injections as the overall lowest number of injections combination (across all administration protocol categories).
[0151] In this embodiment, the method generates separate recommendation tables for loading and maintenance regimens by repeating the above process for loading and maintenance dose combinations. As a result of step 3, four data tables are generated, containing information and parameters for each combination that minimizes the above stratification criteria. Subsets of these tables are shown in Tables 2 through 5 below. Some values in these tables can be derived from values in other columns in multiple ways. For example, the total volume for each dosage form can be calculated by multiplying the number of vials and volume (full vials [#V*Vol.]; partial vials [#V*Vol.]) for each dosage form and then summing them. Alternatively, these can be derived from the total weight of the product contributed by each dosage form. In an embodiment, each value that can be calculated in more than one way is calculated in at least two of these ways to check the internal consistency of the generated data. Similarly, data related to total product and total product should be interconvertible based on data in other columns. In an embodiment, each volume / mg value is compared with its corresponding mg / volume value and / or its constituent volume and / or mg value to check for data consistency.
[0152]
[0153]
[0154]
[0155]
[0156]
[0157]
[0158]
[0159]
[0160]
[0161]
[0162]
[0163]
[0164]
[0165]
[0166]
[0167]
[0168]
[0169]
[0170]
[0171]
[0172]
[0173]
[0174]
[0175]
[0176]
[0177]
[0178]
[0179]
[0180]
[0181]
[0182]
[0183]
[0184]
[0185]
[0186]
[0187]
[0188]
[0189]
[0190] An exemplary implementation of the user interface for the method described above for determining the drug administration regimen for a subject will now be described. Once the table above is calculated by the processor, it can be stored, for example, in memory and used to provide recommendations to the user via the user interface. Alternatively, the user interface can be used to send a request to the processor to perform the calculations described above and generate recommendations on an as-is (i.e., in real time upon receiving a request from the user). For example, the processor can implement steps 1 to 3 above for a single body weight using parameters stored in memory when it receives input body weight via the user interface and optionally selects the criteria on which the recommendations should be based. In this example, the parameters stored in memory may include any of the following: parameters of available dosage forms, maximum available syringe volume, type of dosing regimen (e.g., dose per kilogram per basal period, permissible multiples for basal periods, etc.).
[0191] Figure 3 An exemplary user interface main screen is shown, through which the methods of the present invention can be accessed. The main screen 300 includes a weight input box 310 and a start button 320. Entering weight in box 310 and selecting the start button 320 will send a request to a processor (locally or on a server), which will calculate a recommended dosage regimen based on the weight information, or retrieve an appropriate pre-calculated dosage regimen stored in memory. The processor then provides the user device with the information required to display a results screen 400. An example of the results screen is shown. Figure 4 If the entered weight is outside the preset range, the processor may instead return an error message. Figure 4The results screen 400 shown is divided into two parts: a loading dose section 400A and a maintenance dose section 400B. The loading dose section 400A includes single-dose recommendations 420 that conform to the clinical guidelines described above. This can be obtained from the "TD" columns in Tables 2 and 3 above. The maintenance dose section 400B includes three dose recommendations 430A, 430B, and 430C, reflecting three different administration intervals that conform to the aforementioned clinical guidelines. These can be obtained from the "TD" columns in Tables 4 and 5 above. The results screen 400 also includes a criterion selection drop-down menu 410. In the example shown, the selected criterion is the default "residual optimization" (i.e., minimum loss), although alternative configurations are possible. Through this drop-down menu 410, the user can select different criteria to prioritize when choosing a recommended dosing regimen, where the selection of the preferred criterion will result in the selection of one of the two different hierarchical structures described above. A new selection via the drop-down menu may cause the results screen 400 to refresh to display the corresponding recommended dosing regimen. In the example shown, the results page is generated by outputting information from Tables 2 and 4 above, specifically for the loading dose section 400A and the maintenance dose section 400B. If the "Minimum Injection" option is selected in the drop-down menu 410, the page is refreshed to include the data selected from Tables 3 and 5, respectively. Standard dose recommendations 430B and 430C for optimizing all types of dosing regimens are labeled 440. This information can be extracted from the "Minimum Loss in All Maintenance Regimens" column in Table 4. Each section further includes "Details" buttons 450A and 450B, which lead to... Figure 5 The details screen shown.
[0192] Figure 5A loading dose details interface 500 is shown that can be used to output a recommended loading dose protocol to a user. A similar interface (not shown) for maintenance dose is generated using the details button 450B. In this embodiment, the maintenance dose details interface (not shown) includes three panels, one panel for each type of dosing protocol (weekly, bi-weekly, four-weekly). In other embodiments, the maintenance dose details interface may include a single dosing protocol that has been determined to be optimal among all types of dosing protocols. The loading dose details interface 500 includes an optimization criteria drop-down menu 510 and details about the recommended loading dose based on the currently selected optimization criteria. The details include: a total dose 520 extracted from the “TD” column of Tables 2 through 5 (Table 2 is used in this case); a total volume 530 extracted from the “TV” column of Tables 2 through 5 (Table 2 is used in this case); a warning 560 extracted from the “VCC” column of Tables 2 through 5 (Table 2 is used in this case) indicating the use of two different concentrations of vials; and vial information 540 (for each dosage form in Tables 2 through 5, which vials should be used, the amount to be used from the “#V” and “#Vol.” columns, and the number of vials to be used). Interface 500 also includes an “Injection Details” button 550. Button 550 enables the processor to provide the information necessary to display the injection details screen 600, and an example of this is shown in... Figure 6 As shown in A. The "Injection Details" screen 600 includes an injection details panel 650, which provides details for each administration 650A, 650B extracted from the "Inj." column of Tables 2 through 5. Screen 600 further includes a residual calculation 660 (extracted from the "W4" column of Tables 2 through 5), a total dose detailed calculation 670 (extracted from the "Wt" and "TD" columns of Tables 2 through 5), and a total volume calculation 680 (extracted from the "#V," "#Vol.", and "mg" columns for each dosage form in Tables 2 through 5).
[0193] The term "computer system" includes hardware, software, and data storage devices for embodying a system or method of execution according to the embodiments described above. For example, a computer system may include a central processing unit (CPU), input devices, output devices, and data storage, which may be implemented as one or more connected computing devices. Preferably, the computer system has a display or includes computing devices having a display for providing visual output (e.g., in the design of a business process). Data storage may include RAM, disk drives, or other computer-readable media. A computer system may include multiple computing devices connected via a network and capable of communicating with each other through the network.
[0194] The methods described above can be provided as a computer program, a computer program product, or a computer-readable medium carrying the computer program, which is configured to perform one or more of the methods described above when run on a computer.
[0195] The term "computer-readable medium" includes, but is not limited to, any one or more non-transitory media that can be directly read and accessed by a computer or computer system. Such media may include, but is not limited to, magnetic storage media such as floppy disks, hard disks, and magnetic tapes; optical storage media such as optical discs or CD-ROMs; electrical storage media such as memory, including RAM, ROM, and flash memory; and mixtures and combinations of the above storage media, such as magnetic / optical storage media.
[0196] Unless the context otherwise requires, the description and definition of the features set forth above are not limited to any particular aspect or embodiment of the invention and are equally applicable to all aspects and embodiments described.
[0197] As used herein, “and / or” will be regarded as a specific disclosure of each of the two specified features or components, with or without the other. For example, “A and / or B” will be regarded as a specific disclosure of each of (i) A, (ii) B, and (iii) A and B, as if each were set forth separately herein.
[0198] It is important to note that, as used in the specification and appended claims, the singular forms “a,” “an,” and “the” include plural objects unless the context explicitly specifies otherwise. A range herein may be expressed as from “about” a particular value, and / or to “about” another particular value. When such a range is expressed, another embodiment includes from one particular value and / or to another particular value. Similarly, when a value is expressed as an approximation using the antecedent “about,” it will be understood that the particular value forms another embodiment. The term “about” in relation to numerical values is optional and, for example, indicates + / - 10%.
[0199] Throughout this specification, including the following claims, unless the context otherwise requires, the words “comprising” and “including”, as well as variations such as “comprising,” “including,” and “including”, shall be understood to imply inclusion of the said whole or step or group of whole or steps, but not to exclude any other whole or step or other group of whole or steps.
[0200] Other aspects and embodiments of the invention provide for the aspects and embodiments described above, wherein the term “comprising” is replaced by the terms “consisting of” or “substantially consisting of”, unless the context otherwise requires.
[0201] Features disclosed in the foregoing description, or in the following claims, or in the accompanying drawings, expressed in their particular form or according to the means for performing the disclosed functions, or the methods or processes for obtaining the disclosed results, may, where appropriate, be used alone or in any combination of these features to implement the invention in different forms.
[0202] While the invention has been described in conjunction with the exemplary embodiments described above, many equivalent modifications and variations will be apparent to those skilled in the art when this disclosure is given. Therefore, the exemplary embodiments of the invention described above are to be considered illustrative rather than restrictive. Various changes may be made to the described embodiments without departing from the spirit and scope of the invention.
[0203] To avoid any ambiguity, any theoretical explanations provided herein are intended to improve the reader's understanding. The inventor does not wish to be bound by any of these theoretical explanations.
[0204] Any chapter headings used in this article are for organizational purposes only and should not be construed as limiting the topics described.
[0205] All references cited in this specification are incorporated herein by reference in their entirety.
Claims
1. A computer-implemented method for determining a drug administration regimen for a subject, the method comprising: Receive the value of at least one parameter associated with the subject; The amount of drug (A) to be administered to the subject per basic time period (t) is determined at least in part based on the value of at least one parameter associated with the subject. t The drug is available in a variety of different dosage forms (D1, D2), wherein at least two of the different dosage forms have different drug concentrations in the dosage forms; Calculate all minimum combinations of the at least two different dosage forms (A) t [D1, D2, D1D2]), the minimum combination can be used to achieve the amount of drug (A) to be administered to the subject. t The minimum combination is defined as the minimum number of doses of each dosage form in the combination (D1, D2, D1D2) that reaches or exceeds the amount of drug to be administered to the subject (A). t (combination of ) Select the combination that meets the criteria (A) t A subset of [D1, D2, D1D2]), wherein the standard comprises at least a first standard and a second standard, wherein the first standard and the second standard are selected from a set of standards, the set of standards comprising: A standard applies to the value of the total loss associated with the combination, wherein the loss (W) associated with the dosage form combination t [D1, D2, D1D2];W n1t [D1, D2, D1D2];W n2t [D1, D2, D1D2]) is the total amount of drug in the dosage form combination and the amount of drug to be administered to the subject (A). t A n1t A n2t ) difference, The standard applicable to the total number of physical application steps associated with the combination, and A standard applicable to the total number of physical preparation steps associated with the combination; and Output a subset of the selected combinations as one or more optimal administration regimens for the subject.
2. The method according to claim 1, wherein at least two of the multiple different dosage forms differ in the total amount of drug in the dosage form.
3. The method according to claim 1 or 2, wherein: Select the combination (A) t The subset of [D1, D2, D1D2] that satisfies at least the first and second criteria includes: Select the combination (A) according to the first criterion. t The first subset of [D1, D2, D1D2], and A second subset of the combination is selected from the first subset according to a second criterion different from the first criterion; and Outputting a subset of the selected combinations as one or more optimal administration regimens for the subject includes outputting the last selected subset of combinations as one or more optimal administration regimens for the subject.
4. The method of claim 3, wherein the method further comprises selecting a third subset of the combination from the second subset according to a third criterion.
5. The method according to claim 1 or 2, wherein, The method further includes: The amount of drug (A) to be administered to the subject is calculated for the basic time period (t) of one or more multiples (n). n1t A n2t );as well as Calculations for each of the basic time periods (t) for the plurality of multiples (n) can be used to determine the amount of drug (A) to be administered to the subject. n1t A n2t All minimum combinations of at least two different dosage forms.
6. The method according to claim 5, wherein the method comprises: The combination (A) is selected for the basic time period (t) and the basic time period (t) of each of the multiples (n). t [D1,D2, D1D2];A n1t [D1, D2, D1D2];A n2t A subset of [D1, D2, D1D2]); as well as The output is a subset of the combinations selected for the base time period (t) and the base time period (t) for each of the multiples (n).
7. The method according to claim 5, wherein the method comprises: The combination (A) is jointly selected for the basic time period (t) and the basic time periods (t) of all the multiples (n). t [D1,D2, D1D2];A n1t [D1, D2, D1D2];A n2t A subset of [D1, D2, D1D2]).
8. The method according to claim 1 or 2, wherein, The method includes receiving values of one or more further parameters associated with the subject, the one or more further parameters including: a selection to be used as the first criterion, a selection to be used as the second criterion, or both.
9. The method according to claim 1 or 2, wherein, The method includes calculating losses (W) associated with dosage form combinations. t [D1, D2, D1D2];W n1t [D1, D2, D1D2];W n2t [D1, D2, D1D2]) represents the total amount of drug in the dosage form combination and the amount of drug to be administered to the subject (A). t A n1t A n2t The difference between the two is used to calculate the total loss as the loss for each time period.
10. The method according to claim 9, wherein, One of the first and second criteria applies to the value of the total loss associated with each selected combination.
11. The method according to claim 1 or 2, wherein, The method further includes calculating the total number of physical application steps required to apply the combination.
12. The method according to claim 11, wherein, One of the first and second criteria applies to the total number of physical application steps associated with each selected combination.
13. The method according to claim 1 or 2, wherein, The method further includes calculating the total number of physical preparation steps required to apply the combination, wherein one of the first criterion and the second criterion applies to the total number of physical preparation steps associated with each selected combination.
14. The method according to claim 1 or 2, wherein, The method is implemented by a computing device including a user interface, receiving the value of at least one parameter associated with the subject includes the computing device receiving information input by the user via the user interface, and outputting one or more optimal administration protocols includes the computing device providing the user with information identifying the one or more optimal administration protocols via the user interface.
15. The method of claim 1 or 2, wherein the method is implemented by a computing device configured to communicate with a second computing device, receiving the value of at least one parameter associated with the subject includes the computing device receiving information from the second computing device, and outputting one or more optimal administration protocols includes the computing device transmitting information identifying the one or more optimal administration protocols to the second computing device.
16. The method according to claim 5, wherein, The multiple (n) is an integer multiple.
17. The method of claim 16, wherein the basic time period (t) is selected from: a day, a week, and a month.
18. The method according to claim 1 or 2, wherein: The drug can be obtained in three dosage forms (D1, D2, D3), the drug can be obtained in four dosage forms (D1, D2, D3, D4), the drug can be obtained in five dosage forms (D1, D2, D3, D4, D5), or the drug can be obtained in six dosage forms (D1, D2, D3, D4, D5, D6); and At least two of the dosage forms differ from each other in drug concentration at the dosage of the dosage form.
19. A computing device comprising a processor and a memory, wherein, The computing device is configured to determine a drug administration regimen for the subject by implementing the method according to any one of claims 1-18.
20. A computer-readable medium having instructions recorded thereon, which, when executed by a processor, cause the processor to perform the steps of the method according to any one of claims 1-18.
